Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Inclusion criteria:

- Male or non-pregnant, non-lactating female patients at least 18 years of age

- Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6
months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of
78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)

- Rheumatoid factor and anti-CCP antibodies negative

- Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥2cm
diameter or nail changes consistent with psoriasis or documented history o plaque
psoriasis

Exclusion criteria:

- Chest X-ray with evidence of ongoing infectious or malignant process

- Subjects who have previously been treated with more than 3 different TNFα inhibitors

- Subjects taking high potency opioid analgesics

- Subjects who have ever received biologic immunomodulating agents except for those
targeting TNFα Other protocol-defined inclusion/exclusion criteria may apply